Muscle Invasive Urothelial Carcinoma
Advertisement
Perioperative durvalumab with gemcitabine/cisplatin in patients with resectable MIBC resulted in high EFS and OS at 2 years.
Dr. Sonpavde expounds on the current state and momentum of research efforts to advance treatment strategies in MIBC.
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Dr. Satkunasivam details the RAD VACCINE MIBC trial, an evaluation of the efficacy and safety of neoadjuvant sasanlimab.
Dr. Satkunasivam explains the momentum for an IO-plus-radiation strategy in MIBC, as well as the potential of sasanlimab.
The COXEN model is used to select genes for predicting tumor cell response to a specific drug treatment.
dd-MVAC provides a better OS at 5 years compared with GC in the perioperative setting for patients with MIBC.
Dr. Deek highlights his analysis of NRG RTOG 0524 and 0712 for prognostic significance of immune cell infiltration in MIBC.
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.
Drs. Koshkin and Basu comment on the best available treatment approach for patients with ctDNA-positive MIBC after surgery.
Researchers compared maximal transurethral resection followed by concurrent chemoradiation with radical cystectomy.
A recent exploratory analysis examined patients with MIBC who were treated with radical radiotherapy and concomitant drugs.
The minimally invasive options available to patients diagnosed with muscle-invasive disease of urothelial origin are limited.
A recent study correlated cell-free tumor DNA sequencing with response to neoadjuvant chemotherapy in patients with N+ MIBC.
TAR-200 consists of a small silicone delivery system that provides sustained, local release of gemcitabine to the bladder.
The RaDar assay tracks up to 48 tumor-specific variants in cell-free DNA in a cancer patient’s blood plasma.
Daniel M. Geynisman, MD, explains the results and utility of the RETAIN trial for bladder sparing in patients with MIBC.
Matthew Galsky, MD, contextualizes HCRN GU 16-257 as a potential game-changer for bladder sparing in patients with MIBC.
IAC-RT may be a useful and tolerable treatment option for patients with MIBC who are unfit for radical cystectomy.
Researchers examined the impact of care fragmentation on patients receiving neoadjuvant chemotherapy and radical cystectomy.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.